The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients

被引：22

作者：

Nelson, David R. ^{[1
]}

机构：

[1] Univ Florida, Clin & Translat Sci Inst, Gainesville, FL 32610 USA

来源：

LIVER INTERNATIONAL | 2011年 / 31卷

关键词：

boceprevir; direct-acting antiviral agents; hepatitis C; novel therapies; protease inhibitors; resistant mutations; telaprevir; PEGINTERFERON ALPHA-2A; DISEASE PROGRESSION; PLUS RIBAVIRIN; UNITED-STATES; TELAPREVIR; INFECTION; PREVALENCE;

D O I：

10.1111/j.1478-3231.2010.02391.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

With the introduction of direct-acting oral antiviral agents we are on the verge of a new era that will transform the treatment landscape. This review discusses recent developments in drug discovery for hepatitis C protease inhibitors. First generation protease inhibitors will offer higher sustained viral response rates in naive populations when combined with standard pegylated interferon and ribavirin. However, these dramatic gains will be partially offset by new challenges in viral resistance and increased adverse events.

引用

页码：53 / 57

页数：5

共 16 条

[1] The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 [J].

Armstrong, Gregory L. ;

Wasley, Annemarie ;

Simard, Edgar P. ;

McQuillan, Geraldine M. ;

Kuhnert, Wendi L. ;

Alter, Miriam J. .

ANNALS OF INTERNAL MEDICINE, 2006, 144 (10) :705-714

[2] Protease and polymerase inhibitors for the treatment of hepatitis C [J].

Asselah, Tarik ;

Benhamou, Yves ;

Marcellin, Patrick .

LIVER INTERNATIONAL, 2009, 29 :57-67

[3] Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression [J].

Davis, Gary L. ;

Alter, Miriam J. ;

El-Serag, Hashem ;

Poynard, Thierry ;

Jennings, Linda W. .

GASTROENTEROLOGY, 2010, 138 (02) :513-U141

[4]

Everson GT, 2009, HEPATOLOGY, V50, p1025A

[5] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].

Fried, MW ;

Shiffman, ML ;

Reddy, KR ;

Smith, C ;

Marinos, G ;

Goncales, FL ;

Haussinger, D ;

Diago, M ;

Carosi, G ;

Dhumeaux, D ;

Craxi, A ;

Lin, A ;

Hoffman, J ;

Yu, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982

[6] Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection [J].

Hezode, Christophe ;

Forestier, Nicole ;

Dusheiko, Geoffrey ;

Ferenci, Peter ;

Pol, Stanislas ;

Goeser, Tobias ;

Bronowicki, Jean-Pierre ;

Bourliere, Marc ;

Gharakhanian, Shahin ;

Bengtsson, Leif ;

McNair, Lindsay ;

George, Shelley ;

Kieffer, Tara ;

Kwong, Ann ;

Kauffman, Robert S. ;

Alam, John ;

Pawlotsky, Jean-Michel ;

Zeuzem, Stefan .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (18) :1839-1850

[7] Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients [J].

Kieffer, Tara L. ;

Sarrazin, Christoph ;

Miller, Janice S. ;

Welker, Martin W. ;

Forestier, Nicole ;

Reesink, Hendrik W. ;

Kwong, Ann D. ;

Zeuzem, Stefan .

HEPATOLOGY, 2007, 46 (03) :631-639

[8] Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial [J].

Kwo, Paul Y. ;

Lawitz, Eric J. ;

McCone, Jonathan ;

Schiff, Eugene R. ;

Vierling, John M. ;

Pound, David ;

Davis, Mitchell N. ;

Galati, Joseph S. ;

Gordon, Stuart C. ;

Ravendhran, Natarajan ;

Rossaro, Lorenzo ;

Anderson, Frank H. ;

Jacobson, Ira M. ;

Rubin, Raymond ;

Koury, Kenneth ;

Pedicone, Lisa D. ;

Brass, Clifford A. ;

Chaudhri, Eirum ;

Albrecht, Janice K. .

LANCET, 2010, 376 (9742) :705-716

[9] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].

Manns, MP ;

McHutchison, JG ;

Gordon, SC ;

Rustgi, VK ;

Shiffman, M ;

Reindollar, R ;

Goodman, ZD ;

Koury, K ;

Ling, MH ;

Albrecht, JK .

LANCET, 2001, 358 (9286) :958-965

[10] Fibrosis and disease progression in hepatitis C [J].

Marcellin, P ;

Asselah, T ;

Boyer, N .

HEPATOLOGY, 2002, 36 (05) :S47-S56

← 1 2 →